Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13494634 | 1.00 | AGER (0.40) | AGERTLR9GAALMNAMAPK1 | |
| SCHEMBL17460394 | 1.00 | AGER (0.40) | AGERTLR9GAALMNAMAPK1 | |
| SCHEMBL343964 | 0.83 | TLR9 (0.44) | TLR9GAALMNAMAPK1CA1 | |
| SCHEMBL18409155 | 0.81 | TLR9 (0.42) | TLR9GAALMNAMAPK1CA1 | |
| SCHEMBL17142083 | 0.75 | F2 (0.44) | TLR9GAALMNAMAPK1CA1 | |
| SCHEMBL19023731 | 0.75 | F2 (0.44) | TLR9GAALMNAMAPK1CA1 | |
| SCHEMBL10547922 | 0.74 | KMT2A (0.43) | GAALMNACA2DHODHKMT2A | |
| SCHEMBL10547930 | 0.74 | KMT2A (0.43) | GAALMNACA2DHODHKMT2A | |
| SCHEMBL8817515 | 0.73 | TLR9 (0.48) | AGERTLR9GAALMNAMAPK1 | |
| SCHEMBL8952094 | 0.72 | ALDH1A1 (0.44) | TLR9GAALMNAMAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| CN-108473498-B | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10131669-B2 | Pyrazolopyrimidine compounds | PFIZER INC. (US) | 2018-11-20 | — | — | US | disclosed |
| EP-3394066-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| EP-3172210-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | Pfizer Inc (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016012896-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131669-B2 | Pyrazolopyrimidine compounds | PDE4B, PDE4A, PDE7A | AGER 3430/4885TLR9 4846/4885GAA 1284/4885 |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | AGER 1693/4885TLR9 28/4885GAA 4404/4885 |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | AGER 839/4885TLR9 30/4885GAA 4340/4885 |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | DPYD, QDPR, ABCG2 | AGER 3996/4885TLR9 4274/4885GAA 2097/4885 |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | AGER 1693/4885TLR9 28/4885GAA 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.